Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

University of Guelph

$24,800.00

Development of an in vitro assay to evaluate veterinary ophthalmologic therapies.

FY 2013-14

Summary
Veterinary drugs to treat eye diseases in dogs represent a large and growing market sector throughout North America. Eye problems are common in animals, and effective medical management of these conditions often requires repeated treatment with specific medications. The development of new medications is a key area for future market growth with significant potential to provide high-value employment opportunities for Canadians in pharmacy, manufacturing and sales/marketing. Significant economic benefits are also likely to accrue through growth at veterinary clinics following the development and implementation of new therapies. Presently, the development of new veterinary drugs is hampered to some extent by the relative lack of non-invasive (ie. without actual animal testing) methods to assess whether cells from the dog eye will be damaged by candidate drugs, and whether such drugs will be effective. This proposal, if successful, will seek to develop assays using cultured corneal cells isolated previously, with which the safety and effectiveness of prospective eye medications (under development or already in use in humans) can be easily determined without invasive testing. Cells will be grown in culture dishes in a manner that mimics the structure and function of the normal dog cornea. The cultures will be subjected to physical or chemical insults that model the types of injuries or diseases suffered naturally by dogs. The cultures will then be treated with different test medications to determine whether or not the rate and quality of healing is improved, and whether the cells are further damaged by the candidate drug treatment. The development of an effective assay for the assessment of eye drugs in dogs should significantly enhance the potential for drug development by the industry partner (Merck) and could substantially enhance Canadian participation in this market sector.
Program
Engage Grants Program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
452177-2013
Name nom
LaMarre, Jonathan
Department département
Biomedical Sciences
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
24800
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
505
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Veterinary pharmaceuticals
Area of application fr
Produits pharmaceutiques à usage vétérinaire
Research subject code
5512
Research subject group en
Animal biology
Research subject group fr
Biologie animale
Research subject en
Veterinary sciences
Research subject fr
Médecine vétérinaire
Partie
1
Nb partie
1
Application title
Development of an in vitro assay to evaluate veterinary ophthalmologic therapies.
Keyword
NSERC
Application summary
Veterinary drugs to treat eye diseases in dogs represent a large and growing market sector throughout North America. Eye problems are common in animals, and effective medical management of these conditions often requires repeated treatment with specific medications. The development of new medications is a key area for future market growth with significant potential to provide high-value employment opportunities for Canadians in pharmacy, manufacturing and sales/marketing. Significant economic benefits are also likely to accrue through growth at veterinary clinics following the development and implementation of new therapies. Presently, the development of new veterinary drugs is hampered to some extent by the relative lack of non-invasive (ie. without actual animal testing) methods to assess whether cells from the dog eye will be damaged by candidate drugs, and whether such drugs will be effective. This proposal, if successful, will seek to develop assays using cultured corneal cells isolated previously, with which the safety and effectiveness of prospective eye medications (under development or already in use in humans) can be easily determined without invasive testing. Cells will be grown in culture dishes in a manner that mimics the structure and function of the normal dog cornea. The cultures will be subjected to physical or chemical insults that model the types of injuries or diseases suffered naturally by dogs. The cultures will then be treated with different test medications to determine whether or not the rate and quality of healing is improved, and whether the cells are further damaged by the candidate drug treatment. The development of an effective assay for the assessment of eye drugs in dogs should significantly enhance the potential for drug development by the industry partner (Merck) and could substantially enhance Canadian participation in this market sector.